Scarica l'app Stockscreener
2.31
0.43%
-0.010
Dopo l'orario di chiusura:
2.30
-0.01
-0.43%
Precedente Chiudi:
$2.32
Aprire:
$2.26
Volume 24 ore:
1.66M
Relative Volume:
0.91
Capitalizzazione di mercato:
$462.79M
Reddito:
$314.00K
Utile/perdita netta:
$-40.23M
Rapporto P/E:
-8.25
EPS:
-0.28
Flusso di cassa netto:
$-84.71M
1 W Prestazione:
+12.14%
1M Prestazione:
+63.83%
6M Prestazione:
+29.78%
1 anno Prestazione:
+37.50%
Intervallo 1D:
$2.18
$2.3299
Intervallo di 1 settimana:
$2.0801
$2.3799
Portata 52W:
$1.03
$2.565
Atai Life Sciences N V Stock (ATAI) Company Profile
Nome
Atai Life Sciences N V
Settore
Industria
Telefono
49 89 2153 9035
Indirizzo
WALLSTRASSE 16, BERLIN
Confronta ATAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
2.31 | 412.70M | 314.00K | -40.23M | -84.71M | -0.28 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-03 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
| 2021-11-11 | Iniziato | ROTH Capital | Buy |
| 2021-10-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-01 | Iniziato | Jefferies | Buy |
| 2021-07-13 | Iniziato | Berenberg | Buy |
| 2021-07-13 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-13 | Iniziato | Cantor Fitzgerald | Buy |
| 2021-07-13 | Iniziato | Citigroup | Buy |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-13 | Iniziato | Credit Suisse | Outperform |
| 2021-07-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Atai Life Sciences N V Borsa (ATAI) Ultime notizie
atai Life Sciences to Participate in Upcoming Investor Conferences - Yahoo
2 ‘Strong Buy’ Psychedelic Stocks To Scoop Up ASAP - Barchart.com
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors - Benzinga
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know - Nasdaq
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy? - sharewise
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? - Yahoo Finance
atai Life Sciences holds annual general meeting - Investing.com Australia
atai Life Sciences holds annual general meeting By Investing.com - Investing.com India
ATAI Life Sciences Approves Key Governance Changes - TipRanks
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies - Yahoo Finance
ATAI Life Sciences Sees Significant Rise in Borrow Rate | ATAI S - GuruFocus
ATAI Stock Poised for Growth After Positive Phase 2a Data on BPL - GuruFocus
ATAI Stock Poised for Growth After Positive Phase 2a Data on BPL-003 | ATAI Stock News - GuruFocus
ATAI Life Sciences (ATAI) Shows Encouraging Mid-Stage Trial Resu - GuruFocus
atai Life Sciences reports positive data from mid-stage depression trial - Seeking Alpha
ATAI Reiterates a 'Buy' Rating with a Price Target of $10 | ATAI Stock News - GuruFocus
Atai Life Sciences Reports Positive Phase 2a Results for Treatment-Resistant Depression Drug - marketscreener.com
ATAI Life Sciences Reports Promising Findings from Depression Study | ATAI Stock News - GuruFocus
atai reports positive phase 2a results for depression treatment By Investing.com - Investing.com UK
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression - Yahoo Finance
How Do Things Look For ATAI Life Sciences N.V (NASDAQ: ATAI) In The Short-Term? - Stocksregister
Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt - simplywall.st
ATAI Explores Psychedelic Solutions for Veterans' Mental Health - GuruFocus
ATAI Explores Psychedelic Solutions for Veterans' Mental Health | ATAI Stock News - GuruFocus
Atai Life Sciences: Progress in Psychedelic Mental Health Treatments - TipRanks
Will Atai Get A New Lease Of Life? - RTTNews
Atai Life Sciences Reports First Quarter 2025 Financial Results - marketscreener.com
ATAI Reports Significant First Quarter Revenue Growth | ATAI Sto - GuruFocus
ATAI Sees Financial Boost with Cash Reserves Rise | ATAI Stock N - GuruFocus
ATAI Reports Significant First Quarter Revenue Growth | ATAI Stock News - GuruFocus
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - The Manila Times
Certain Restricted stock units of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Certain Options of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
ATAI Begins Phase 2 Study for Social Anxiety Treatment | ATAI St - GuruFocus
Atai Life Sciences Announces First Patient Dosed In Phase 2 Study Of Emp-01 For The Treatment Of Social Anxiety Disorder - marketscreener.com
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder - Yahoo
ATAI Life Sciences Repays Hercules Loan Early - TipRanks
Daily Market Movement: ATAI Life Sciences N.V (ATAI) Sees a -2.00 Decrease, Closing at 1.47 - DWinneX
ATAI Life Sciences N.V [ATAI] Records 50-Day SMA of $1.4948 - knoxdaily.com
ATAI Life Sciences N.V: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - investchronicle.com
Have you been able to find a good deal on ATAI Life Sciences N.V’s shares? - uspostnews.com
Atai Life Sciences N.V. Announces Executive Changes - marketscreener.com
ATAI Life Sciences N.V (ATAI)’s Market Momentum: Closing Strong at 1.51, Down -3.82 - DWinneX
An Analysis of ATAI Life Sciences N.V (ATAI)’s Potential Price Growth - knoxdaily.com
ATAI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
ATAI Life Sciences N.V [ATAI] stock for 65,560 USD was sold by Kirpekar Sahil - knoxdaily.com
How Will ATAI Life Sciences N.V (NASDAQ: ATAI) Perform In Months To Come? - Marketing Sentinel
Investing in ATAI Life Sciences N.V (ATAI) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating - Seeking Alpha
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
At What Point In Time Would I Choose To Purchase ATAI Life Sciences N.V (NASDAQ: ATAI) Stock? - stocksregister.com
Atai Life Sciences N V Azioni (ATAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):